This review is devoted to the studies of the role of modern markers of myocardial and renal damage (high sensitivity troponin T [hsTnT] and urinary neutrophil gelatinase-associated lipocain [NGA/lipocalin-2] in patients with chronic heart failure (CHF). It contains description of nature, mechanism of synthesis, and release of hsTnT and NGAL, problems of variability of determination of these biomarkers, consideration of causes of elevation of their activity in CHF. Both hsTnT and NGAL have high diagnostic and prognostic significance. Determination of these biomarkers in combination with natriuretic peptides gives complimentary information for more accurate stratification of risk of development of possible complications. Measurement of activity of hsTnT and NGAL (lipocalin-2) will make it easier for a physician to solve the problem of optimization of therapy and management of a concrete patient.